← Back to guidelines
Oncology5 papers

Malignant neoplasm of biliary tract

Last edited: 4/10/2026

Overview

Malignant neoplasms of the biliary tract (BTC) are aggressive and highly fatal malignancies. Advances in understanding the molecular landscape have led to new therapeutic options, though surgery remains the only potentially curative therapy with frequent recurrence 1.

Diagnosis

No information provided in the abstracts.

Management

  • Surgery is the only potentially curative therapy for BTC 1.
  • Adjuvant treatment with capecitabine may improve overall survival (OS) and relapse-free survival in BTC 1.
  • Concomitant chemoradiotherapy may be considered following R1 resection in BTC 1.
  • Upfront systemic chemotherapy is the treatment of choice for unresectable locally advanced BTC 1.
  • Locoregional therapy may be considered after an initial period of at least 3-4 months of systemic chemotherapy for unresectable BTC 1.
  • Cisplatin plus gemcitabine is the standard treatment for metastatic BTC 1.
  • Special Populations

    No information provided in the abstracts.

    Key Recommendations

  • Adjuvant treatment with capecitabine may improve OS and relapse-free survival in biliary tract cancer (BTC) 1. (Evidence: Moderate)
  • Upfront systemic chemotherapy is the treatment of choice for unresectable locally advanced BTC 1. (Evidence: Expert opinion)
  • Cisplatin plus gemcitabine constitutes the standard treatment for metastatic BTC 1. (Evidence: Expert opinion)
  • References

    1 Gómez-España MA, Montes AF, Garcia-Carbonero R, Mercadé TM, Maurel J, Martín AM et al.. SEOM clinical guidelines for pancreatic and biliary tract cancer (2020). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2021. link

    Original source

    1. [1]
      SEOM clinical guidelines for pancreatic and biliary tract cancer (2020).Gómez-España MA, Montes AF, Garcia-Carbonero R, Mercadé TM, Maurel J, Martín AM et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2021)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG